Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor Conference
20 Novembro 2007 - 11:00AM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 20 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that the
Company will participate in the 2007 Lazard Capital Markets
Healthcare Investor Conference in New York. The Company's
presentation will take place at 3:00 p.m. (Eastern) on Wednesday,
November 28, 2007. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
Allos website home page and investor relations section. The webcast
will be available for replay on Allos' website through December 14,
2007. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in
a pivotal Phase 2 (PROPEL) trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The PROPEL trial is being
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment, or SPA
process. The Company is also investigating PDX in patients with
non-small cell lung cancer and a range of lymphoma sub-types. The
Company's other product candidate is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors and non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's
website at http://www.allos.com/. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional
information concerning these forward-looking statements and other
factors that may cause actual results to differ materially from
those anticipated in the forward-looking statements is contained in
the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2006 and in the Company's
other periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice
President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)